Related Experiment Video
Updated: Jun 30, 2026

In Vitro Modeling of Down Syndrome Neurogenesis Using Human-Induced Pluripotent Stem Cells
Published on: March 7, 2025
Trisomy 21 enhances human fetal erythro-megakaryocytic development
Stella T Chou1, Joanna B Opalinska, Yu Yao
1Division of Hematology, The Children's Hospital of Philadelphia, PA, USA
Insights
Down syndrome (trisomy 21) in fetal blood cells promotes excessive growth of red blood and platelet precursors. This may increase the risk of developing leukemia later in life.
Area of Science:
- Hematology
- Genetics
- Developmental Biology
Background:
- Children with Down syndrome (DS) have increased risks for transient myeloproliferative disorder (TMD) and acute megakaryoblastic leukemia (AMKL).
- Both conditions involve abnormal blood cell precursors (blasts) with GATA1 mutations, but the role of trisomy 21 itself in fetal hematopoiesis is unclear.
- DS is characterized by an extra copy of chromosome 21, impacting gene expression and cellular development.
Purpose of the Study:
- To investigate how trisomy 21 affects fetal blood formation independently of GATA1 mutations.
- To understand the cellular basis for the increased risk of TMD and AMKL in individuals with Down syndrome.
Main Methods:
- Studied hematopoiesis in trisomy 21 fetal liver cells using in vitro assays.
- Employed mouse transplantation models to assess the function of trisomy 21 hematopoietic progenitors.
- Analyzed cell proliferation and differentiation patterns.
Main Results:
- Trisomy 21 fetal liver progenitors showed enhanced production of erythroid and megakaryocytic cells.
- These progenitors exhibited excessive proliferation in a cell-autonomous manner.
- Normal GATA1 alleles were present, indicating trisomy 21's direct impact.
Conclusions:
- Trisomy 21 directly promotes the overgrowth of red blood and platelet precursor cells in the fetal liver.
- This expansion of susceptible progenitor cells may create a pre-leukemic state, increasing the risk for TMD and AMKL development.
- Understanding these early events is crucial for preventing hematologic malignancies in Down syndrome.
Abstract:
Children with Down syndrome exhibit 2 related hematopoietic diseases: transient myeloproliferative disorder (TMD) and acute megakaryoblastic leukemia (AMKL). Both exhibit clonal expansion of blasts with biphenotypic erythroid and megakaryocytic features and contain somatic GATA1 mutations. While altered GATA1 inhibits erythro-megakaryocytic development, less is known about how trisomy 21 impacts blood formation, particularly in the human fetus where TMD and AMKL originate. We used in vitro and mouse transplantation assays to study hematopoiesis in trisomy 21 fetal livers with normal GATA1 alleles. Remarkably, trisomy 21 progenitors exhibited enhanced production of erythroid and megakaryocytic cells that proliferated excessively. Our findings indicate that trisomy 21 itself is associated with cell-autonomous expansion of erythro-megakaryocytic progenitors. This may predispose to TMD and AMKL by increasing the pool of cells susceptible to malignant transformation through acquired mutations in GATA1 and other cooperating genes.
More Related Videos
06:40Mouse Fetal Liver Culture System to Dissect Target Gene Functions at the Early and Late Stages of Terminal Erythropoiesis
Published on: September 9, 2014
09:39Generation of Induced Pluripotent Stem Cells from Turner Syndrome (45XO) Fetal Cells for Downstream Modelling of Neurological Deficits Associated with the Syndrome
Published on: December 4, 2021
Related Concept Videos
Karyotyping
Meiosis I
Meiosis vs. Mitosis
Before the start of mitosis and meiosis I, the cell synthesizes DNA, resulting in two homologous copies of each chromosome. DNA synthesis is...
Nondisjunction
Nondisjunction
Teratogenicity